🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#NEWS: Phase 3 data from three studies of our investigational treatment for adults with #MultipleSclerosis have been published by NEJM and presented during a plenary session at #AANAM Learn more ⬇️

#NEWS: Our medicine with Regeneron has been approved by the U.S. FDA for certain patients aged 12 years and older with #ChronicSpontaneousUrticaria (CSU), a chronic inflammatory skin disease. Read more ⤵️

Our first quarter 2025 results are now available. Read the press release. ⤵️ #SanofiResults $SAN $SNY

We’re proud to be teaming up with McLaren Racing on the legendary 24 Hours of Le Mans – carrying not just speed and innovation, but a powerful message. 💛💜💙 Read more ➡️ spkl.io/6018fLr2E #DefeatMeningitis #MeningitisFlag Meningitis Research

#NEWS: New data at #ATS2025 will showcase our scientific leadership and breadth of innovation in chronic inflammatory respiratory conditions, including #COPD and #asthma. Read about our data ⬇️ CC: Regeneron

Accelerating the journey from discovery to life-changing health solutions. Today, Sanofi is innovating rapidly to build a safer, healthier tomorrow. Explore what’s next at #VivaTech with @Sanofi 💜

We’re acquiring Vigil Neuroscience, adding a potential first-in-class neuroinflammation treatment to our R&D pipeline. A Phase 2 Alzheimer’s study is planned—because patients urgently need new options. Learn more. ⤵️

#NEWS: First real-world comparison of infant and maternal respiratory syncytial virus (#RSV) immunization programs to be presented at #ESPID2025. Read more ⬇️

We’re providing an update on our phase 3 studies in adults with COPD: spkl.io/6018fftlM CC: Regeneron

We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases.

The U.S. FDA has granted Orphan Drug Designation to our investigational therapy for the treatment of #SickleCellDisease, reinforcing our dedication to developing new medicines that address unmet needs for people living with #RareDiseases. Learn more ⬇️

#NEWS: New data at #ASCO25 published in Journal of Clinical Oncology analyzed the potential of an investigational delivery method to administer our investigational subcutaneous #MultipleMyeloma combination therapy.  Learn more ⬇️

#News: At ISTH 2025, we’re sharing new data in immune thrombocytopenia (#ITP) and #hemophilia that demonstrate our commitment to supporting the varied needs of people living with #RareBloodDisorders. Learn more about our research and scientific innovation ⬇️

We’re sharing results from phase 4 research in patients with skin of color diagnosed with #AtopicDermatitis at #RAD2025. Read more about the data. 📣 CC: Regeneron

#NEWS: We’re accelerating global shipments of our respiratory syncytial virus (#RSV) immunization aimed at all infants to ensure broad availability well ahead of the RSV season. Read more ⬇️

#NEWS: At #EULAR2025, we presented new data evaluating our investigational therapy in active IgG4-related disease, a progressive immune-mediated rare disease. Read about our data ⬇️

At #EAACI2025, we’re presenting new late-breaking data from our phase 4 head-to-head study in patients with chronic rhinosinusitis with nasal polyps (#CRSwNP) and coexisting asthma. Find out more about the results ⬇️ CC: Regeneron